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Migraine – a suitable case for treatment?
Headache disorders are common, with a lifetime prevalence of over 90% in all
populations where they have been measured. So common, in fact, that a Global
Campaign to Reduce the Burden of Headache was launched in 2004 to educate health
care providers, the general public, and national governments to recognize that
headache disorders are not trivial, that effective treatments are available, and that the
costs of treatment are small in comparison to lost productivity in the workplace (Steiner
2004). Thus, although headache rarely signals serious underlying disease, it is one
of the most frequent causes for consulting family practitioners and neurologists – 1
in 6 and 1 in 3 respectively. In many countries, however, headache disorders are
regarded as unimportant and self-limiting and not as proper disease entities. Allocation
of health care resources is often minimal, despite the consensus conference of the
American and International Headache Societies conclusion that migraine, for example,
is under-diagnosed and under-treated throughout the world.
Although tension-type headache is the most prevalent of the headache disorders,
migraine is the most disabling (Rasmussen 1995). Migraine is a chronic neurological
disorder characterized by recurrent attacks of headache and other symptoms, which
may last for up to 3 days. The pain is moderate to severe and is accompanied by
phonophobia, photophobia, nausea, and vomiting. Prodromal symptoms may include
somnolence and mood changes, while some patients may experience aura which is a
complex of focal neurological symptoms including visual disturbances, numbness,
paraesthesia and speech difficulties. The current International Classification of
Headache Disorders (IHSCC 2004) provides diagnostic criteria for up to 7 subtypes
of migraine. It mostly affects people of working age but also occurs in older adults
and children. European and American studies have shown a prevalence of about
18% among females and 6.5% among males, aged 12 years and older. Similar patterns
are seen in Central and South America, but migraine appears to be somewhat less
common in Asia and Africa (WHO/WFN 2004). The universally higher rate in women,
at about 2–3 times that in men, is probably hormonally driven. The burden of migraine
varies, with some individuals experiencing many more attacks and associated
disorders while others may have no more than a monthly attack (Bigal et al 2004;
Rasmussen 1995). At the top end, 35% of American women with migraine experience
1–4 severe attacks per month while a further 25% of them experience 4 or more
severe attacks per month. Migraine places a considerable burden on the sufferer,
their family and friends, and upon society as a whole, with 80% of American migraine
sufferers reporting some form of disability. The economic and public health burdens
of migraine are significant, and include reduced work and school productivity; lost
work productivity alone is estimated to cost about US$13 billion annually in the
USA (Hu et al 1999). Extrapolation for migraine prevalence and attack incidence
data suggest that 3000 migraine attacks occur daily for each million of the general
population, placing migraine 19th among all causes of years lost to disability (YLDs)
(WHO 2001).
Proper management of migraine is therefore of paramount concern, and treatment
should be optimalized for individual patients. Different types of medicines are
available for the pharmacological treatment of migraine, and can be seen as preventive,
Roger M.Pinder
‘s-Hertogenbosch, The NetherlandsNeuropsychiatric Disease and Treatment 2006:2(3) 246
Pinder
acute or combined treatments. In this issue of
Neuropsychiatric Disease and Treatment, all three
approaches to migraine management are reviewed. Garza
and Swanson (2006) review the prophylaxis of migraine,
an approach to be considered whenever migraine
significantly interferes with the patient’s daily activities
despite acute treatment, when acute treatments have failed,
are overdosed or are associated with adverse effects, and
where rare migraine conditions can potentially cause
neurological damage. Evidence-based guidelines have stated
the goals for preventive treatment to be (1) to reduce attack
frequency, severity, and duration; (2) to improve
responsiveness to treatment of acute attacks; and (3) to
improve function and reduce disability. The US Headache
Consortium (USHC 2000) has issued treatment guidelines
after extensive evidence-based reviews, grouping
medications with proven high efficacy and mild to moderate
adverse effects (amitriptyline, valproate, propranolol,
timolol), those with lower efficacy and mild to moderate
adverse effects (other beta-blockers, calcium channel
blockers, NSAIDs, fluoxetine, gabapentin), and the
remainder with limited or unproven efficacy or limiting
adverse effects. Since that evaluation of the evidence
available up to 1997, a number of newer agents have become
available, including the anti-epileptic topiramate which now
has regulatory approval in Europe and the USA for migraine
prevention. D’Amico and colleagues (2006) review the
evidence base for topiramate, concluding that slow titration
to the optimum dose gives high responsiveness and good
tolerability. In view of the lack of weight gain and of major
contraindications, they recommend topiramate as a first-line
option for migraine prophylaxis.
There are a number of abortive therapy options for
treating acute attacks of migraine, including NSAIDs, non-
opiate analgesics, and combination analgesics, but the
favored options today are the migraine-specific triptans.
Lainez (2006) reviews one of the more recent introductions,
rizatriptan, and suggests that it is at least as effective as
other migraine-specific agents in the acute treatment of
migraine but with a more consistent long-term efficacy
across multiple attacks. Combined treatment with triptans
and NSAIDs seems to be associated with better efficacy
than either type of agent alone especially in patients with
many disabling attacks and low response to a single agent.
Krymchantowski (2006) reviews the potential of various
combinations before concluding that the best evidence is
available for the combination of sumatriptan and naproxen.
Treatment of migraine has come a long way in recent
years. The introduction of the first migraine-specific abortive
agent, the 5-HT1B/1D agonist sumatriptan, considerably
enhanced our knowledge of the pathophysiology of
migraine, and enhanced the quality of life for many migraine
sufferers. Acute treatment is now fairly satisfactory for many
patients, and even the difficult cases can respond to a
combination of triptans and NSAIDs. Better agents for
prophylaxis are still needed, and will probably emerge from
a deeper understanding of exactly how our current agents
work and from our growing knowledge on the
neurophysiology of migraine attacks.
References
Bigal ME, Lipton RB, Stewart WF. 2004. The epidemiology and impact
of migraine. Curr Neurol Neurosci Rep, 4:98–104.
D’Amico D, Grazzi L, Bussone G, et al. 2006. Topiramate in the prevention
of migraine: a review of its efficacy, tolerability, and acceptability.
Neuropsychiatric Disease and Treatment, 2:261–7.
Garza I, Swanson JW. 2006. Prophylaxis of migraine. Neuropsychiatric
Disease and Treatment, 2:281–91.
Hu XH, Markson LE, Lipton KB et al. 1999. Burden of migraine in the
United States: disability and economic costs. Arch Int Med, 159:813–
18.
[IHSCC] International Headache Society Classification Committee. 2004.
The International Classification of Headache Disorders, 2nd ed.
Cephalalgia, 24(Suppl 1): 9–160.
Krymchantowski AV. 2006. The use of combination therapies in the acute
management of migraine. Neuropsychiatric Disease and Treatment,
2:293–7.
Láinez MJA. 2006. Rizatriptan in the treatment of migraine.
Neuropsychiatric Disease and Treatment, 2:247–59.
Rasmussen BK. 1995. Epidemiology of headache. Cephalalgia, 15:45–
68.
Steiner TJ. 2004. Lifting the burden: the global campaign against headache.
Lancet Neurol, 3:204–5.
[USHC] United States Headache Consortium. 2000. Practice parameter:
Evidence-based guidelines for migraine headache. Report of the
Quality Standards Subcommittee of the American Academy of
Neurology, American Academy of Neurology. p 1–11.
[WHO/WFN] World Health Organization/World Federation of Neurology.
2004. Atlas: Country resources for neurological disorders. Geneva:
WHO. p 50.
[WHO] World Health Organization. 2001. The World Health Report 2001
– Mental Health, New Understanding, New Hope. Geneva: WHO. p.
22–4.